Key Drivers
- Liquidity Strength
- Heavy Cash Burn
- High R&D Spend
AIAI Summary
BHVN has shifted from a pure cash-burn biotech to a near-term catalyst stock with multiple late-stage shots on goal, but the investment case now hinges on whether opakalim and BHV-1300 deliver registrable efficacy before high burn and binary trial risk trigger a sharp reversal.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Liquidity Strength
- •Heavy Cash Burn
- •High R&D Spend
BHVN remains a pre-revenue biotech with improving liquidity and a stronger balance sheet, but persistent heavy losses, high cash burn, and a still-rich valuation keep the risk profile elevated.
Price Behavior
Key Price Behavior Insights:
- •Higher lows
- •New support
- •Overbought risk
BHVN has surged over the last month from $10.13 to $15.96 with higher lows and a firm $14.78-$14.96 support zone, but the move is now stretched and needs confirmation above $15.96.
Steep rally from $10.13 to $15.96 suggests short-term overextension
Sentiment & News
Key News Insights:
- •Phase 3 start
- •Epilepsy enrollment
- •Mixed analyst views
Biohaven is making steady late-stage progress in epilepsy and autoimmune disease, highlighted by BHV-1300's Phase 3 launch and opakalim's completed enrollment, though analyst sentiment remains mixed ahead of key data.
The news is modestly positive overall, as pipeline milestones support longer-term value but near-term share performance may stay volatile until pivotal results arrive
Similar Companies in Healthcare
Other companies in the same sector with AI ratings